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Abstract
Background: Voiding dysfunctions are a common problem that has a severe negative impact on the quality of life.
Today there is a need for new drug targets for these conditions. The role of ATP receptors in bladder physiology
has been studied for some time, primarily in animal models. The aim of this work is to investigate the localization
of the ATP receptors P2X2, P2X3 and P2X7 and their colocalization with vimentin and actin in the human urinary
bladder.
Methods: Immunohistochemical analysis was conducted on full-thickness bladder tissues from fundus and
trigonum collected from 15 patients undergoing open radical cystectomy due to chronic cystitis, bladder
cancer or locally advanced prostate cancer. Colocalization analyses were performed between the three different P2X
subtypes and the structural proteins vimentin and actin. Specimens were examined using epifluorescence microscopy
and correlation coefficients were calculated for each costaining as well as the mean distance from the laminin positive
basal side of the urothelium to the vimentin positive cells located in the suburothelium.
Results: P2X2 was expressed in vimentin positive cells located in the suburothelium. Less distinct labelling of P2X2 was
also observed in actin positive smooth muscle cells and in the urothelium. P2X3 was expressed in vimentin positive cells
surrounding the smooth muscle, and in vimentin positive cells located in the suburothelium. Weaker P2X3 labelling was
seen in the urothelium. P2X7 was expressed in the smooth muscle cells and the urothelium. In the suburothelium, cells
double positive for P2X2 and vimentin where located closer to the urothelium while cells double positive for P2X3 and
vimentin where located further from the urothelium.
Conclusion: The results from this study demonstrate that there is a significant difference in the expression of the
purinergic P2X2, P2X3 and P2X7 receptors in the different histological layers of the human urinary bladder.
Background
Functional bladder disturbances are very common and
have a negative impact on the quality of life for the af-
fected individuals. Today, disturbances in the filling and
voiding of the urinary bladder are primarily treated with
substances interfering with the cholinergic signalling sys-
tem, i.e. antimuscarinic drugs. These drugs are initially
effective, but have adverse effects that are often associ-
ated with poor compliance and persistence with treat-
ment [1]. Therefore, it is highly relevant to investigate
alternative targets. Forty years ago, purinergic receptors
were suggested to be an important component of the
non-adrenergic, non-cholinergic (NANC) transmission
in the urinary bladder [2], and ever since, there have
been several reports on the importance of the purinergic
signalling system in the urinary bladder based on both
functional and histological studies [3–8].
Purinergic signalling is mediated via the release of
ATP and its metabolites. The P2X receptors are ion-
channels [9, 10] and there are several reports on these
receptors being present in the urinary bladders of differ-
ent species [7, 11–13]. However, most studies performed
on human urinary bladders have investigated individual
cell types [5–7] or performed quantitative PCR analysis
of whole urinary bladders [14].
Several different P2X subunits have been described in
the urinary bladder. In the present work we have limited
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ourselves to investigate the distribution of P2X2, P2X3
and P2X7 subunits in relation to actin and vimentin in
the human urinary bladder. We have chosen to look at
P2X2, P2X3 and P2X7 since they have different pharma-
cological properties. P2X2 is slowly desensitizing, P2X3
is fast desensitizing and P2X7 is non-desensitizing [15].
P2X2 and P2X3 are believed to be involved in the neu-
roeffector unit [16] and P2X7 has been shown to be in-
volved in inflammatory responses [17] as well as in actin
reorganisation [18]. Even though the P2X3 receptor has
been found both on interstitial cells (ICs) and afferent
nerve endings in the human urinary bladder its expres-
sion in the smooth muscle layer has not been fully inves-
tigated [6]. P2X2 is commonly expressed together with
P2X3 in P2X2/3 heterotrimers and in this regard it is inter-
esting to compare the distribution of these subtypes [10].
Materials and methods
Tissue
All experiments presented in this paper were approved by
the Regional Ethics Committee at Karolinska University
Hospital (Dnr. 2010/574-32, 2009/1481-32, 2008/1633-31)
and all samples were collected from patients after retrieval
of written informed consent according to the declaration
of Helsinki.
Human urinary bladder tissue was collected from 6
male and 9 female patients (age range 58–82 years,
mean age 72 years) undergoing open radical cystec-
tomy due to chronic cystitis, bladder cancer or locally
advanced prostate cancer. All patients were screened
for ongoing urinary tract infection prior to surgery.
All patients received prophylactic perioperative anti-
biotic treatment. Patients were also screened for co-
morbidities that could pose as contraindications for
the surgery such as disseminated malignant disease or
severe heart failure. All collected tissue was fixed in 4 %
formaldehyde (Apoteket, Gothenburg, Sweden) , cryopro-
tected before frozen in Tissue Tek O.C.T. (Sakura Finetek
Sweden AB, Gothenburg, Sweden) and sectioned in 10 μm
sections using a MICROM HM 525 cryostat (MICROM
International GmbH, Walldorf, Germany).Sampled tissues
from the bladder trigonum and fundus were all taken from
macroscopically tumor free areas, as determined by the
pathologists at the Department of Pathology and Oncology
and encompassed the full bladder thickness (urothelium,
submucosa/lamina propria, smooth muscle, and serosa).
All bladders were investigated microscopically by a path-
ologist and are matched with a pathology report verifying
the diagnosis.
Immunofluorescence
Slides were pre-incubated in PBS containing 0.05 % Triton
X-100 and 0.2 % bovine serum albumin (BSA; both from
Sigma-Aldrich, St Louis, USA). Slides were then incubated
with primary antibodies; rabbit anti-P2X2 (1:50; H-116;
Santa Cruz Biotechnology Cat# sc-25693, RRID:AB_21579
14) [19], rabbit anti-P2X3 (1:50; H-60; Santa Cruz Bio-
technology Cat# sc-25694, RRID:AB_2158071) [19, 20],
rabbit anti-P2X7 (1:50; H-265; Santa Cruz Biotechnology
Cat# sc-25698, RRID:AB_2158373) [21], goat anti-vimentin
(1:250; C-20; Santa Cruz Biotechnology Cat# sc-7557, RRI-
D:AB_793998) [22] and rabbit anti-laminin (1:200; Sigma-
Aldrich Cat# L9393, RRID:AB_477163) [23] diluted in PBS
containing 0.05 % Triton X-100 and 0.2 % BSA over-night
in a moist chamber at room temperature. All antibodies
were raised against human antigens except anti-laminin
which was raised against basement membrane of Engleb-
reth Holm-Swarm (EHS) mouse sarcoma. After washing in
PBS, the slides were incubated in different mixtures of spe-
cies-specific goat or donkey secondary antibodies conju-
gated with Dylight488 (1:500; Jackson ImmunoResearch
Laboratories, Inc, West Grove, USA), Alexa Fluor 568,
Alexa Fluor 488 (1:200; Lifetechnology, Carlsbad, USA)
and/or actin-binding TRITC-phalloidin (1 μg/ml; Sigma-
Aldrich) for one hour at room temperature in a moist
chamber. Slides were then rinsed in PBS before
mounted with Dako Fluorescence Medium (DakoCytoma-
tion, Glostrup, Denmark) to prevent fading. Secondary
antibody specificity was assessed by omitting the pri-
mary antibody.
Immunofluorescence microscopy and image analyses
Immunofluorescence image acquisition was performed
using a Nikon Eclipse 800 fluorescence microscope
equipped with a Nikon DXM1200 digital camera and
Nikon ACT-1 version 2.10 software. Image analysis was
conducted using Image J (U. S. National Institutes of
Health). Mean distance was calculated by measuring the
distance from the border between urothelium and sub-
urothelium to three different cells per image, which la-
belled positive for both vimentin and P2X2 or P2X3
respectively. The border between the suburothelium and
the urothelium was verified by immunoreactivity to lam-
inin in the basal membrane and could be identified both
in vimentin and P2X labelled images. The mean distance
for these cells was calculated for each image. Images
were assembled using the free- and open source pro-
gram GIMP (GNU Image Manipulation Program)2.6.11
developed by The GIMP Development Team freely
available at www.gimp.org. Schematic drawing was cre-
ated using the free- and open source program Inkscape
0.48 developed by The Inkscape Team freely available at
inkscape.org.
Analysis of data
Results from colocalization analysis are expressed with
Pearson’s correlation coefficient and Manders’ overlap
Svennersten et al. BMC Urology  (2015) 15:81 Page 2 of 9
coefficient as described by Manders et al. [24]. Pearson’s






















Ri and Gi are grey values of pixel i from the red and
green channel of a dual-color image. 8-bit grey scale im-
ages acquired from the red and green channel was corre-
lated with each other. Full scale uncropped images were
used for all analysis except in Fig. 4 where the cells of
interest were outlined using the Image J ROI-tool before
analysis. Mean and standard error of the mean (SEM) of
the Pearson’s correlation coefficient and Manders’ overlap
coefficient were calculated for the different combinations
of costaining. To test for significant differences in colocali-
zation, the Student’s unpaired t-test was used to compare
two means and ANOVA followed by Bonferroni post-hoc
test was used for multiple comparisons (Microsoft Excel
with ad-in Data Analysis) as recommended by McDonald
et al. [25]. A p-value < 0.05 was considered statistically sig-
nificant. Pearson’s correlation coefficient and Manders’
overlap coefficient was calculated using the Image J plugin
colocalization finder (developed by Cristophe Laum-
monerie and Jerome Mutterer at Institut de Biologie
Moleculaire des Plantes, Strasbourg, France) and Intensity
correlation analysis (from Wright cell imaging facility,
www.uhnres.utoronto.ca/facilities/wcif/). No image pro-
cessing or background subtraction was performed before
calculation of Pearson’s correlation coefficient. Before cal-
culation of Manders’ overlap coefficient, the background
of all images was subtracted using Image J plugin ROI
background subtract. Graph-plotting was conducted using
Microsoft Excel.
Results
P2X expression in the human urinary bladder smooth
muscle layer
The immunoreactivity for the P2X2 receptor in the
smooth muscle layer of the human urinary bladder was
moderate. The predominant P2X2 immunoreactivity was
observed in smooth muscle cells and in vimentin posi-
tive cells located in the periphery, as well as, in between
the smooth muscle bundles (Fig. 1a). P2X3 immunoreac-
tivity was present in vimentin positive cells but absent in
the smooth muscle cells (Fig. 1b). P2X7 immunoreactiv-
ity was seen in the smooth muscle cells. No P2X7 label-
ling was observed in vimentin positive cells located in
the muscle layer. This observation was confirmed by the
low correlation between vimentin and P2X7 immunore-
activity in the smooth muscle layer of the human urinary
bladder (Fig. 1c-d). By calculating the Pearson´s correl-
ation coefficient between vimentin and the different re-
ceptor subtypes, we observed that there was a significant
variation between the different P2X receptors analysed
with the relation P2X3 > P2X2> > P2X7 with regards to
colocalisation with vimentin (Fig. 1d). This relationship
was also present when data from the trigonum and the
fundus of the bladder were analysed separately but there
were no significant differences in the Pearson´s correl-
ation coefficient between trigonum and fundus for the
respective P2X receptors. Also, by using Manders’ over-
lap coefficient analysis, a significant difference in coloca-
lization with vimentin between P2X3 and P2X7 was
obtained (Table 1).
In order to distinguish between the smooth muscle
ICs and muscle cells, which showed immunoreactivity
for P2X3 and P2X7 respectively, the bladder tissues were
costained for vimentin and actin filaments using anti-
vimentin antibodies and TRITC-conjugated phalloidin,
respectively. The smooth muscle bundles were intensely
labelled by the phalloidin, revealing high actin content,
while actin labelling of the vimentin positive ICs was
negligible as compared to actin labelling of the smooth
muscle. This is illustrated by the low correlation between
the labelling of vimentin and actin (Fig. 2a, d). Subsequent
costaining of P2X3 with TRITC-phalloidin showed that the
immunoreactivity of the P2X3 in vimentin positive ICs was
significantly separated from the phalloidin labelled smooth
muscle (Fig. 2b, d). The P2X7 receptor subtype and actin
were both intensely labelled and their localization in the
muscle bundles correlated well with each other (Fig. 2c-d).
The Pearson’s-correlation coefficient for P2X7 and actin
was significantly higher than for P2X3 and actin as well as
for actin and vimentin (Fig. 2d). Also, by using Manders’
overlap coefficient a significant difference in colocalization
with actin between P2X7 and P2X3 was seen (Table 1).
P2X expression in the human urinary bladder urothelium
and suburothelium
The border between urothelium and suburothelium was
visualised using polyclonal antibodies against laminin
which is abundant in the basal membrane of the human
bladder (Fig. 3). P2X2 immunoreactivity was observed in
vimentin positive cells in the urinary bladder suburothe-
lium verified by calculating Manders’ overlap coefficient
for single cells (Figs. 3 and 4). P2X2 was also observed
in the urothelium, primarily in apical cells and to a lesser
extent in urothelial cells located in the basal and inter-
mediate layer of the urothelium (Fig. 3 and 5). Abundant
P2X3 receptor immunoreactivity was seen in vimentin
positive cells and in the urothelium (Figs. 3, 4 and 5).
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The P2X7 receptor immunoreactivity was absent in
vimentin positive cells but present in apical cells in the
bladder urothelium (Figs. 3 and 5).
The P2X3 immunoreactivity was commonly more in-
tense compared to P2X2 and P2X7 in vimentin positive
cells located in the suburothelium. The intensity of the la-
belling of vimentin positive cells followed the order
P2X3 > P2X2 > P2X7 and were significantly different from
each other (normalised intensity was 1.53 ± 0.07 for P2X3,
1.29 ± 0.03 for P2X2 and 1.16 ± 0.02 for P2X7). There was
no significant difference in the intensity of the labelling of
the purinergic receptors between the trigonum and the
fundus of the bladder. The distribution of vimentin posi-
tive cells in the suburothelium was heterogenous with a
dense layer of vimentin positive cells close to the urothe-
lium and an area of more sparsely distributed vimentin
positive cells closer to the smooth muscle. Also, the loca-
tion of cells positive for the different P2X receptors varied
in the suburothelium. By measuring the distance from the
basal side of the urothelium to the vimentin positive cells
that were most intensely labelled for the respective P2X
receptors, we found that the most intense P2X2 labelling
was on average 73 ± 14 μm from the urothelium while
P2X3 was 186 ± 25 μm from the urothelium. Generally,
there was a greater distance between vimentin positive
cells and the urothelium in the trigonum than in the fun-
dus but this difference was not significant.
Discussion
We have used antibodies against the purinergic receptor
subunits P2X2, P2X3 and P2X7 to show that these receptor
subunits are expressed differently throughout the histo-
logical layers of the human urinary bladder. P2X2 is present
in vimentin positive cells of the suburothelium and in the
vicinity of the smooth muscle bundles, and to some extent
in the smooth muscle and urothelium. P2X3 is found in
the urothelium and in vimentin positive cells located in the
suburothelium as well as in vimentin positive cells sur-
rounding smooth muscle bundles. The expression of P2X7
is predominantly localized to the smooth muscle cells of
the human urinary bladder but also to some extent in the
apical cells of the urothelium (Fig. 6). Hence, P2X2, P2X3
Table 1 Manders’ overlap coefficient for P2X in smooth muscle
layer (mean ± SEM)
P2X3 P2X7 p-value
Vimentin 0.69 ± 0.03 0.43 ± 0.03 1.63*10−5
Actin 0.53 ± 0.04 0.86 ± 0.03 6.07*10−7
Fig. 1 Vimentin and P2X receptor immunostaining in human urinary bladder smooth muscle layer. a-c. Costaining (yellow) of the smooth muscle
layer with vimentin (green) and P2X (red), including scatterplot of red and green pixel intensities. Sections are from a patient with bladder cancer.
d. Pearson’s correlation coefficient for vimentin (green channel) and P2X (red channel) expressed as mean ± SEM (P2X2: n = 11, P2X3: n = 15 and
P2X7: n = 14). *p < 0.017 and ***p < 0.00017 for Bonferroni adjusted levels of significance. Scale bar = 100 μm
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and P2X7 receptors might have different roles in the differ-
ent histological parts of the urinary bladder.
The variation in expression of the different P2X recep-
tor subunits in the different layers of the urinary bladder
is interesting, since these receptors may have a role as
mechanoreceptors when they respond to autocrine ATP
signalling due to mechanical stress. The suburothelium of
the urinary bladder is rich in ICs and these are suggested
to play an important role in the transduction of mechan-
ical input from the urothelium to the detrusor muscle. ICs
in the urinary tract have been found to modulate the
excitability of smooth muscle cells upon nerve stimu-
lation [26] and to be of importance for contractile re-
sponses [27]. Interstitial cells are of mesenchymal origin
and vimentin has extensively been used as a marker for
ICs in the urinary bladder [6, 11, 28]. However, vimentin
has also been suggested to be important in cellular mech-
anical stability, migration and contractile capacity [29] and
it has been demonstrated that ATP can induce vimentin
reorganization [30]. In our study, we have observed both
P2X2 as well as P2X3 immunoreactivity in vimentin posi-
tive cells in the suburothelium of the human urinary blad-
der. However, the localization of P2X2 and P2X3
expression in vimentin positive cells varied in relation to
the distance from the urothelium. P2X2 was generally lo-
cated closer to the urothelium while P2X3 was on average
located closer to the smooth muscle. In agreement with a
current study [31] our results show that vimentin positive
cells have different purinergic immunoreactive phenotypes
based on their location in the bladder suburothelium. In
addition, since both P2X2 and P2X3 immunoreactivity
was observed in vimentin positive cells located in the
smooth muscle layer, our results further suggest that
vimentin positive cells vary phenotypically based on their
histological location in the urinary bladder.
In the current study, P2X2 and particularly P2X7 were
expressed in actin positive detrusor smooth muscle cells.
The role of P2X7 in the actin rich muscle cell layer is espe-
cially intriguing since ATP binding to P2X7 can cause actin
cytoskeleton reorganization with subsequent cellular signal-
ing [6] and release of cytokines in inflammatory cells [18].
These findings are interesting with regard to our study be-
cause P2X7 have a role in inflammation in general and
functional bladder disabilities often have an inflammatory
component. This may suggest a connection between
symptoms from the bladder and pathologies with an
underlying inflammatory component such as the meta-
bolic syndrome [32].
Fig. 2 Actin and vimentin or P2X receptor immunostaining in human urinary bladder smooth muscle layer. a. Costaining (yellow) of the smooth
muscle layer with actin (red) and vimentin (green), with scatterplot of red and green pixel intensities. Section is from a patient with
prostate cancer. b-c. Smooth muscle layer double labelled with P2X (green) and actin (red) with scatterplot of red and green pixel
intensities. Sections are from a patient with bladder cancer. d. Pearson’s correlation coefficient for actin (red channel) and P2X/vimentin (green
channel) expressed as mean ± SEM (n = 9). *p < 0.017 and **p < 0.0017 for Bonferroni adjusted levels of significance. Scale bar = 100 μm
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The human bladder urothelium forms a tight barrier
between the lumen and the internal milieu of the urinary
bladder. It also plays an important role in bladder
mechanosensation with both autocrine and paracrine
signalling functions [6]. The human bladder urothelium
is a stratified epithelium comprising highly specialised
apical cells, the umbrella cells. Recently, there have
been several interesting reports on the organisation
and development of the urothelial cells [33]. These
reports suggest that the development of the different
layers in the stratified urothelium is not a continuous
process, but rather that the umbrella cells have their
own lineage originating from a subclass of cells in the
basal layer. In the current study we observed that all
three investigated P2X receptors are expressed in the
umbrella cells. Furthermore, P2X3, and to a lesser ex-
tent, P2X2 immunoreactivity was observed in the en-
tire human urothelium. Due to the cellular complexity of
the urothelium there are conflicting reports related to pro-
tein expression in the urothelium particularly, the expres-
sion of the purinergic receptors (reviewed in [34]). In the
current study, no immunoreactivity in the human urothe-
lium was obtained when the tissue sections were incubated
with the secondary antibody alone. Indeed, this control for
antibody specificity has been questioned but P2X2 and
P2X3 has previously been demonstrated in human urothe-
lium [35] and P2X7 in the rat urothelium [36].
The organized distribution of different P2X subtypes
in the human urinary bladder is of clinical and pharma-
cological significance. This is especially intriguing, since
there are interesting results from animal studies that
show that the increased micturition frequency seen in
older animals is accompanied with an increase of puri-
nergic signalling and a decrease of cholinergic [37].
There are also indications that anticholinergic treatment
of overactive bladder syndrome may shift the balance
Fig. 3 Laminin, vimentin and P2X receptor immunostaining in human urinary bladder urothelium and suburothelium. Top panel; Double immunostaining
of vimentin (green) and laminin (red). Arrows indicate anti-laminin labelling of the basal membrane. Section is from a patient with prostate cancer.
Scale bar = 100 μm. Following panels; Double immunostaining of vimentin (green) and P2X2, P2X3, and P2X7, respectively (red). Yellow indicates
double immunoreactivity to vimentin and P2X. Sections are from a patient with bladder cancer. Scale bar = 100 μm
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between purinergic and cholinergic transmission to-
wards more of purinergic [38]. This could explain in-
creasing therapy unresponsiveness over time.
Results from these studies as well as the finding of or-
ganized expression of P2X receptors in human bladders
from older patients suggest that the purinergic system
may be a better target if one wants to treat lower urinary
tract symptoms (LUTS). What is promising with our
findings is that there are a number of specific agonists
against specific P2X receptors [39] which raise the hope
of finding efficient drugs with few side effects. The re-
sults from our study is highly relevant for the potential
treatment of LUTS since the bladders used in our study
are from older men and women undergoing cystectomy
by various pathologies associated with LUTS.
A limitation with this study is that we have not been
able to use urinary bladders from healthy individuals. The
urinary bladders are from patients undergoing radical
cystectomy due to bladder cancer, chronic cystitis or lo-
cally advanced prostate cancer. The dissected specimens
have been free of tumour both macro- and microscopic-
ally, but the disease itself can affect local and systemic
physiology. For example, P2X7 expression has been found
to be increased in non-tumour cells in the vicinity of ma-
lignant cells in prostate cancer [40] while the expression
of P2X3 in human bladder urothelium decreases with in-
creased grade of malignancy [41]. Tissue hosting tumours
may also have alterations on a molecular level even
though they have normal histology [42]. However, in our
study we did not see any difference in P2X expression be-
tween bladders that had been removed due to different
diagnosis. Also, our results are comparable to studies per-
formed on healthy animal bladders [36], leading us to in-
terpret purinergic signalling as a general component of
bladder physiology present in unaffected bladders as well
as those affected by disease.
Fig. 4 Top panel; Immunohistochemical labeling of vimentin (green) and P2X2 (red) in human urinary bladder suburothelium. Yellow= immunoreactivity
to both vimentin and P2X2. Arrows indicate cells positive for vimentin and P2X2. Manders’ overlap coefficient for cells indicated by arrows = 0.93 ± 0.01
(mean ± SEM). Sections are from a patient with prostate cancer. Scale bar = 25 μm. Bottom panel; Immunohistochemical labeling of vimentin (green) and
P2X3 (red) in human urinary bladder suburothelium. Yellow = immunoreactivity to both vimentin and P2X3. Arrows indicate cells positive for vimentin
and P2X3. Manders’ overlap coefficient for cells indicated by arrows = 0.87 ± 0.04 (mean ± SEM). Sections are from a patient with prostate cancer.
Scale bar = 25 μm
Fig. 5 Immunohistochemical labeling of purinergic receptors (red) in human urinary bladder urothelium, from left to right: P2X2, P2X3 and P2X7.
Sections are from a patient with prostate cancer. Scale bar = 50 μm
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Conclusions
In this study we show that there is a significant differ-
ence in the expression of the purinergic P2X2, P2X3 and
P2X7 receptors in the different histological layers of the
human urinary bladder. P2X7 is expressed in smooth
muscle, P2X2 in suburothelial cells located closer to the
urothelium, P2X3 in suburothelial cells closer to the
smooth muscle layer and in ICs surrounding muscle
bundles, while all three receptors where expressed in the
urothelium. The organized distribution of different P2X
receptors in the bladder supports the idea that specific
targeting of the different receptors can have different ef-
fects on bladder function.
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